Stevanato Group S.p.A.

STVN Healthcare Medical Instruments & Supplies

Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS fell 25.0%, free cash flow fell 167.0% and total debt rose 9.27%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five, operating cash flow growth for three.

18.90 0.35 −1.82%
Market cap
$5.3B
P/E
33.8×
Fwd P/E
27.5×
Dividend yield
0.33%
F-score
5/9
Altman Z
4.48
Beneish M
−2.79
Dividend safety
63/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Revenue
1,425.27 1,392.03 1,342.16 1,295.97

+8 more TTM periods

Gross Profit
415.14 403.42 389.06 371.33
Operating Income
232.22 233.78 224.92 216.75
EBT
222.82 222.89 213.95 208.11
Income after Tax
156.05 163.08 158.20 155.59
Net Income Common
156.06 163.08 158.21 155.60
EPS (Diluted)
0.56 0.59 0.58 0.57
Shares (Diluted, Weighted)
273.00 272.97 272.95 272.49
Gross Margin
29.13% 28.98% 28.99% 28.65%
EBIT Margin
16.29% 16.79% 16.76% 16.72%
Net Profit Margin
10.95% 11.72% 11.79% 12.01%
Free Cash Flow Margin
(2.43%) (0.73%) 1.09% (2.64%)
EBITDA
341.32 341.11 325.13 311.78
EBIT
232.22 233.78 224.92 216.75

Show all line items

In millions of $ except per-share values · columns are period end dates